Heresco-Levy U - Search Results

1

Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility.

Segman RH, Heresco-Levy U, Finkel B, Inbar R, Neeman T, Schlafman M, Dorevitch A, Yakir A, Lerner A, Goltser T, Shelevoy A, Lerer B. Segman RH, et al. Psychopharmacology (Berl). 2000 Nov;152(4):408-13. doi: 10.1007/s002130000521. Psychopharmacology (Berl). 2000. PMID: 11140333

2

Trial of maintenance neuroleptic dose reduction in schizophrenic outpatients: two-year outcome.

Heresco-Levy U, Greenberg D, Lerer B, Dasberg H, Brown WA. Heresco-Levy U, et al. J Clin Psychiatry. 1993 Feb;54(2):59-62. J Clin Psychiatry. 1993. PMID: 8095259

3

Two-year trial of maintenance neuroleptic dose reduction in schizophrenic out-patients: predictors of relapse.

Heresco-Levy U, Greenberg D, Lerer B, Dasberg H, Brown WA. Heresco-Levy U, et al. Isr J Psychiatry Relat Sci. 1995;32(4):268-75. Isr J Psychiatry Relat Sci. 1995. PMID: 8641856

4

Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia.

Heresco-Levy U, Silipo G, Javitt DC. Heresco-Levy U, et al. Psychopharmacol Bull. 1996;32(4):731-40. Psychopharmacol Bull. 1996. PMID: 8993096 Clinical Trial.

5

Dopamine D4 receptor gene polymorphisms: relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects.

Kohn Y, Ebstein RP, Heresco-Levy U, Shapira B, Nemanov L, Gritsenko I, Avnon M, Lerer B. Kohn Y, et al. Eur Neuropsychopharmacol. 1997 Feb;7(1):39-43. doi: 10.1016/s0924-977x(96)00380-x. Eur Neuropsychopharmacol. 1997. PMID: 9088883 Clinical Trial.

6

Schizophrenia, chronic hospitalization and the 5-HT2C receptor gene.

Segman RH, Ebstein RP, Heresco-Levy U, Gorfine M, Avnon M, Gur E, Nemanov L, Lerer B. Segman RH, et al. Psychiatr Genet. 1997 Summer;7(2):75-8. doi: 10.1097/00041444-199722000-00003. Psychiatr Genet. 1997. PMID: 9285964

7

Serum neuroleptic levels during reduced dose fluphenazine decanoate maintenance therapy.

Heresco-Levy U, Greenberg D, Lerer B, Javitt DC, Brown WA. Heresco-Levy U, et al. Isr J Psychiatry Relat Sci. 1997;34(4):281-9. Isr J Psychiatry Relat Sci. 1997. PMID: 9409085 Clinical Trial.

8

Environment and vulnerability to major psychiatric illness: a case control study of early parental loss in major depression, bipolar disorder and schizophrenia.

Agid O, Shapira B, Zislin J, Ritsner M, Hanin B, Murad H, Troudart T, Bloch M, Heresco-Levy U, Lerer B. Agid O, et al. Mol Psychiatry. 1999 Mar;4(2):163-72. doi: 10.1038/sj.mp.4000473. Mol Psychiatry. 1999. PMID: 10208448

9

Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia.

Segman R, Neeman T, Heresco-Levy U, Finkel B, Karagichev L, Schlafman M, Dorevitch A, Yakir A, Lerner A, Shelevoy A, Lerer B. Segman R, et al. Mol Psychiatry. 1999 May;4(3):247-53. doi: 10.1038/sj.mp.4000511. Mol Psychiatry. 1999. PMID: 10395214

10

Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia.

Segman RH, Heresco-Levy U, Finkel B, Goltser T, Shalem R, Schlafman M, Dorevitch A, Yakir A, Greenberg D, Lerner A, Lerer B. Segman RH, et al. Mol Psychiatry. 2001 Mar;6(2):225-9. doi: 10.1038/sj.mp.4000842. Mol Psychiatry. 2001. PMID: 11317227

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

81 results

Search Page

Filters